VMD Sciences opens managed access path for canine cancer therapy

CURRENT FULL VERSION: VMD Sciences is pointing to a new canine oncology case as proof that global managed access can open treatment options that aren't otherwise available in the U.S. In a January 30, 2026 press release, the company said it supported Dr. Seth Glasser, DVM, DipACVIM (Oncology), at Garden State Veterinary Specialists in New Jersey in importing an EMA-approved tyrosine kinase inhibitor for Jetta, an 8-year-old mixed-breed dog with metastatic mast cell cancer after standard therapies had failed. (static1.squarespace.com)

According to the announcement, Jetta had a low-grade subcutaneous mast cell tumor with lymph node metastasis. VMD Sciences said Dr. Glasser identified the targeted inhibitor as the best next step, but because the product isn't available in the U.S., access required medical records, a prescription, clinical justification, customs clearance, and secondary FDA inspection support. The company framed the case as an example of its managed access program, which it says is designed to help licensed veterinarians obtain therapies approved in other markets. Dr. Glasser, quoted in the release, said the process initially looked daunting but that VMD handled most of the work and the drug arrived within days. (static1.squarespace.com)

The case lands in a disease area where U.S. veterinarians already have some, but not unlimited, targeted options. Palladia (toceranib phosphate) became the first FDA-approved canine cancer therapy in 2009 for mast cell tumors, and it remains a core systemic option in practice. In Europe, masitinib has long been approved for certain non-resectable canine mast cell tumors with mutated c-kit, giving clinicians there another targeted therapy pathway that isn't broadly available to U.S. practices through normal commercial channels. Based on VMD Sciences’ description of an EMA-approved tyrosine kinase inhibitor for metastatic mast cell disease, it's reasonable to infer the imported product may be masitinib, although the company did not name the drug in the materials reviewed. (pfizer.com)

That matters because mast cell tumors are both common and clinically variable. IDEXX said in a February 2026 announcement that mast cell tumors rank among the most common cancers in dogs, and it is expanding both reference-lab and in-clinic tools aimed at earlier detection and faster workup. At the same time, Merck Animal Health has been building out its oncology portfolio, including gilvetmab for dogs with mast cell tumors or melanoma through veterinary oncology specialists. And supportive care is getting more attention too: Jaguar Health said the FDA renewed the conditional approval of Canalevia-CA1 through December 21, 2026 for chemotherapy-induced diarrhea in dogs. The delayed-release crofelemer tablet is intended to reduce chloride ion secretion in the gut and fluid loss without slowing intestinal transit, a mechanism that can matter when diarrhea threatens hydration, nutrition, owner adherence, and the ability to stay on chemotherapy protocol. Jaguar said this is the fifth and final allowable year of conditional approval for that indication, with the confirmatory effectiveness study underway and a full-approval filing planned if the data support it. Together, those developments suggest a category that is becoming more specialized, with new diagnostics, immunotherapy, symptom-management tools, and cross-border access models all entering the conversation. (biospace.com)

The only direct expert reaction publicly available in the source material came from the treating oncologist and VMD Sciences’ founder. Dr. Glasser said the importation process initially looked daunting, but that VMD handled most of the work and the drug arrived within days. Founder Jeff Oliva said managed access programs are common in human medicine but still underused in veterinary care, and argued that regulatory support can help bridge treatment gaps. Those comments come from company materials, so they should be read as interested-party perspectives rather than independent validation. (static1.squarespace.com)

Why it matters: For veterinary professionals, the bigger takeaway isn't just one dog's treatment course. It's that access pathways themselves may be becoming part of advanced oncology practice. In referral settings, especially when surgery, radiation, standard chemotherapy, or approved targeted agents have been exhausted, a compliant route to internationally approved therapies could widen the menu of options for carefully selected patients. That won't make managed access routine, and it won't replace the need for evidence, pharmacovigilance, or clear pet parent counseling on uncertainty, cost, and logistics. But it could give oncologists another lever in cases where the standard formulary runs out before the clinical need does. The parallel trend on the supportive-care side matters too: when adverse effects such as chemotherapy-induced diarrhea can be managed with indication-specific products like crofelemer, clinicians may have a better chance of maintaining quality of life and keeping patients on treatment rather than delaying or discontinuing therapy. (static1.squarespace.com)

There are also practical implications for general practice teams. As diagnostics improve, more dogs with mast cell disease may be identified earlier and staged more precisely, which could increase referrals into oncology before treatment windows narrow. If specialty centers begin using managed access more often, primary care veterinarians may see more questions from pet parents about therapies available abroad, compassionate-use-style pathways, and why some drugs can be accessed only through specialist oversight and regulatory review. And as oncology caseloads grow, primary care teams may also be more involved in monitoring and triaging treatment-related GI adverse effects, where having a conditionally approved, indication-specific option for chemotherapy-induced diarrhea may reduce reliance on ad hoc off-label management alone. (biospace.com)

What to watch: The next signal to watch is whether this remains a one-off access story or becomes a repeatable model, with more documented oncology cases, more sponsor participation, and potentially formal U.S. regulatory filings for therapies that are already established in Europe. It's also worth watching whether Canalevia-CA1 converts its final year of conditional approval into full approval after Jaguar Health's ongoing effectiveness study, which would strengthen the small but growing toolkit of oncology-specific supportive care in dogs. (static1.squarespace.com)